Medical Journals

Roles of Prostanoids in Colon Carcinogenesis and Their Potential Targeting for Cancer Chemoprevention.

Authors:
  • Mutoh Michihiro
  • Takahashi Mami
  • Wakabayashi Keiji

From: Cancer Prevention Basic Research Project, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. mimutoh@gan2.ncc.go.jp

Current pharmaceutical design

  • Publish Date: 2006
  • ISSN: 1381-6128
  • Volume: 12
  • Issue: 19
  • Pages: 2375-82
  • Medium: Print
  • Language: English
  • Citation (JAMA): Mutoh Michihiro, Takahashi Mami, Wakabayashi Keiji, et al. Roles of Prostanoids in Colon Carcinogenesis and Their Potential Targeting for Cancer Chemoprevention.. Curr. Pharm. Des. 2006;12:2375-82

Abstract

Prostanoids are produced in response to numerous growth factors and environmental stimuli. Their synthesis is dependent on two cyclooxygenase (COX) enzymes, COX-1 and COX-2, which are rate-limiting for the production of prostaglandins (PGs) and thromboxanes from free arachidonic acid. Selective inhibitors of both COX forms have the potential to inhibit colon tumorigenesis, and there is abundant documented evidence of elevated expression of COX-2 in colon tumors and a variety of other malignancies. The resultant high level PGE2 production may play an important role in cell proliferation, modulation of apoptosis, angiogenesis, inflammation and immune surveillance. Prostanoids exert their biological actions through binding to eight specific membrane receptors; the four subtypes EP1 to EP4 for PGE2; DP for PGD2; FP for PGF2; IP for PGI2; and TP for thromboxane A2. Recently, genetic and pharmacologic experiments have suggested that all PGE2 receptors can contribute to colon tumorigenesis. Moreover, it is suggested that EP1 and EP4 play roles in polyp formation independently. It is important to determine details of the down-stream signaling pathways of prostanoid receptors for further understanding of the mechanisms of cancer development. Furthermore, it is anticipated that development of specific receptor antagonists will provide new advantageous tools for chemoprevention.

Mesh Headings (Keywords): Animals, Colonic Neoplasms, Humans, Models, Biological, Prostaglandin Antagonists, Prostaglandins, Receptors, Prostaglandin, Signal Transduction


Check for Full Text / PubMed Unique Identifier (PMID): 16842185


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.